<?xml version="1.0" encoding="UTF-8"?>


<article dtd-version="1.0" article-type="research-article">
  <front>
      <journal-meta>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">intejhealeconman</journal-id>
         <journal-id xmlns:xlink="http://www.w3.org/1999/xlink" journal-id-type="jstor">j50020182</journal-id>
         <journal-title-group xmlns:xlink="http://www.w3.org/1999/xlink">
            <journal-title>International Journal of Health Economics and Management</journal-title>
         </journal-title-group>
      
         <publisher>
            <publisher-name>Springer</publisher-name>
         </publisher>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="ppub">21999023</issn>
         <issn xmlns:xlink="http://www.w3.org/1999/xlink" pub-type="epub">21999031</issn>
         <custom-meta-group xmlns:xlink="http://www.w3.org/1999/xlink"/>
      </journal-meta>
      <article-meta xmlns:xlink="http://www.w3.org/1999/xlink">
         <volume xmlns:mml="http://www.w3.org/1998/Math/MathML"
                 xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">16</volume>
         <issue xmlns:mml="http://www.w3.org/1998/Math/MathML"
                xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table">3</issue>
         <issue-id>i40228033</issue-id>
         <article-id pub-id-type="doi">10.2307/45271465</article-id>
         <article-categories>
            <subj-group>
               <subject>RESEARCH ARTICLE</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title>Reforming the Swedish Pharmaceuticals market: consequences for costs per defined daily dose</article-title>
         </title-group>
         <contrib-group>
            <contrib>
               <string-name>
                  <given-names>Mats A.</given-names>
                  <surname>Bergman</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>David</given-names>
                  <surname>Granlund</surname>
               </string-name>
            </contrib>
            <contrib>
               <string-name>
                  <given-names>Niklas</given-names>
                  <surname>Rudholm</surname>
               </string-name>
            </contrib>
         </contrib-group>
         <pub-date pub-type="ppub">
            <day>1</day>
            <month>9</month>
            <year>2016</year>
         </pub-date>
         <fpage>201</fpage>
         <lpage>214</lpage>
      
      
      
      
         <permissions>
            <copyright-statement>© Springer Science+Business Media New York 2016</copyright-statement>
         </permissions>
         <self-uri xlink:href="https://www.jstor.org/stable/45271465"/>
      
      
         <abstract>
            <p>In 2009 and 2010, the Swedish Pharmaceuticals market was reformed. One of the stated policy goals was to achieve low costs for pharmaceutical products dispensed in Sweden. We use price and sales data for off-patent brand-name and generic Pharmaceuticals to estimate a log-linear regression model, allowing us to assess how the policy changes affected the cost per defined daily dose. The estimated effect is an 18% cost reduction per defined daily dose at the retail level and a 34% reduction in the prices at the wholesale level (pharmacies' purchase prices). The empirical results suggest that the cost reductions were caused by the introduction of a price cap, an obligation to dispense the lowest-cost generic substitute available in the whole Swedish market, and the introduction of well-defined exchange groups. The reforms thus reduced the cost per defined daily dose for consumers while being advantageous also for the pharmacies, who saw their retail margins increase. However, pharmaceutical firms supplying off-patent Pharmaceuticals experienced a clear reduction in the price received for their products.</p>
         </abstract>
         <custom-meta-group>
            <custom-meta>
               <meta-name>lang</meta-name>
               <meta-value>eng</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
  </front>
  <back>
    
      <fn-group xmlns:xlink="http://www.w3.org/1999/xlink">
        <title>[Footnotes]</title>
        <fn id="d434e183a1310">
            <label>2</label>
          
            <p>
               <mixed-citation id="d434e190" publication-type="other">
Ministry of Health and Social Affairs (2009a, b).</mixed-citation>
            </p>
        </fn>
      </fn-group>
    
    
      <ref-list>
        <title>References</title>
        <ref id="d434e206a1310">
          
            <mixed-citation id="d434e210" publication-type="other">
Almarsdottir, A. B., Morgall, J. M., &amp; Björnsdottir, I. (2000). A question of emphasis: Efficiency or equality
in the provision of pharmaceuticals. The International Journal of Health Planning and Management,
15(2), 149-161.</mixed-citation>
        </ref>
        <ref id="d434e223a1310">
          
            <mixed-citation id="d434e227" publication-type="other">
Almarsdottir, A. B., Morgall, J. M., &amp; Grimsson, A. (2000). Cost containment of pharmaceutical use in Iceland:
The impact of liberalization and user charges. Journal of Health Services Research &amp; Policy,. doi: 10.
1177/135581960000500209.</mixed-citation>
        </ref>
        <ref id="d434e240a1310">
          
            <mixed-citation id="d434e244" publication-type="other">
Andersson, K., Petzold, M., Sonesson, C, Lonnroth, K., &amp; Carlsten, A. (2006). Do policy changes in the
pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time-series analysis of
cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy, 79, 231-243.</mixed-citation>
        </ref>
        <ref id="d434e257a1310">
          
            <mixed-citation id="d434e261" publication-type="other">
Aneli, A., &amp; Hjelmgren, J. (2002). Implementing competition m the pharmacy sector: Lessons from Iceland
and Norway. Applied Health Economics and Health Policy, 1, 149-156.</mixed-citation>
        </ref>
        <ref id="d434e272a1310">
          
            <mixed-citation id="d434e276" publication-type="other">
Aneli, A. (2004). Nya villkor för apotek och läkemedelsförsäljning -Erfarenheter frân Danmark, Island och
Norge (in Swedish). IHE Working Paper 2004:2.</mixed-citation>
        </ref>
        <ref id="d434e286a1310">
          
            <mixed-citation id="d434e290" publication-type="other">
Anis, A. H., Guh, D. P., &amp; Woolcott, J. (2003). Lowering generic drug prices: Less regulation equals more
competition. Medical Care, 41, 135-141.</mixed-citation>
        </ref>
        <ref id="d434e300a1310">
          
            <mixed-citation id="d434e304" publication-type="other">
Aronsson, T., Bergman, M. A., &amp; Rudholm, N. (2001). The impact of generic drug corn-petition on brand
name market shares -evidence from micro data. Review of Industrial Organization, 19, 423-433.</mixed-citation>
        </ref>
        <ref id="d434e314a1310">
          
            <mixed-citation id="d434e318" publication-type="other">
Barros, P. P., &amp; Nunes, L. C. (2010). The impact of pharmaceutical policy measures: An endogenous structural-
break approach. Social Science and Medicine, 71, 440-450.</mixed-citation>
        </ref>
        <ref id="d434e328a1310">
          
            <mixed-citation id="d434e332" publication-type="other">
Bergman, M. A., &amp; Rudholm, N. (2003). The relative importance of actual and potential competition: Empirical
evidence from the pharmaceuticals market. Journal of Industrial Economics, 51, 455-467.</mixed-citation>
        </ref>
        <ref id="d434e342a1310">
          
            <mixed-citation id="d434e346" publication-type="other">
Brekke, K. R., Grasdal, A. L., &amp; Holmâs, T. H. (2009). Regulation and pricing of pharmaceuticals: Reference
pricing or price cap regulation. European Economic Review, 55, 170-185.</mixed-citation>
        </ref>
        <ref id="d434e357a1310">
          
            <mixed-citation id="d434e361" publication-type="other">
Brekke, K. R., Holmâs, T. H., &amp; Straume, O. R. (2011). Reference pricing, competition, and pharmaceutical
expenditures: Theory and evidence from a natural experiment. Journal of Public Economics, 95, 624-638.</mixed-citation>
        </ref>
        <ref id="d434e371a1310">
          
            <mixed-citation id="d434e375" publication-type="other">
Duso, T., Herr, A., &amp; Suppliet, M. (2014). The welfare impact of parallel imports: A structural approach
applied to the German market for oral anti-diabetics. Health Economics, 25, 1036-1057.</mixed-citation>
        </ref>
        <ref id="d434e385a1310">
          
            <mixed-citation id="d434e389" publication-type="other">
Econ. (2004). Evaluenng av apotekloven och îndexpnssystemet (in Norwegian). Report, 2004, 10.</mixed-citation>
        </ref>
        <ref id="d434e396a1310">
          
            <mixed-citation id="d434e400" publication-type="other">
Ganslandt, M., &amp; Maskus, K. (2004). Parallel imports and the pricing of pharmaceutical products: Evidence
from the European Union. Journal of Health Economics, 25, 1035-1057.</mixed-citation>
        </ref>
        <ref id="d434e410a1310">
          
            <mixed-citation id="d434e414" publication-type="other">
Ghislandi, S., Patrizio, A., &amp; Caludio, J. (2013). The impact of reference pricing in Italy, a decade on. European
Journal of Health Economics, 14, 1-11.</mixed-citation>
        </ref>
        <ref id="d434e424a1310">
          
            <mixed-citation id="d434e428" publication-type="other">
Granlund, D. (2010). Price and welfare effects of a pharmaceutical substitution reform. Journal of Health
Economics, 29(6), 856-865.</mixed-citation>
        </ref>
        <ref id="d434e439a1310">
          
            <mixed-citation id="d434e443" publication-type="other">
Granlund, D., &amp; Köksal-Ayhan, M.Y. (2014). Parallel Imports and Mandatory Substitution Reform: A Kick
or a Muff for Price Competition? The European Journal of Health Economics, in press.</mixed-citation>
        </ref>
        <ref id="d434e453a1310">
          
            <mixed-citation id="d434e457" publication-type="other">
Granlund, D., &amp; Rudholm, N. (2011). Consumer Information and Pharmaceutical Prices: Theory and Evidence.
Oxford Bulletin of Economics and Statistics, 73, 230-254.</mixed-citation>
        </ref>
        <ref id="d434e467a1310">
          
            <mixed-citation id="d434e471" publication-type="other">
Holmberg, C., Kjellberg, H., Axelsson, B. (2003). Läkemedelsdistributionen i Norden -En komparativ studie av
aktörer, resurser och aktiviteter (in Swedish). SSE/EFI Working Paper Series in Business Administration
No 2003:10.</mixed-citation>
        </ref>
        <ref id="d434e484a1310">
          
            <mixed-citation id="d434e488" publication-type="other">
Kanavos, P., Costa-Font, J., &amp; Seeley, E. (2008). Competition in off-patent drug markets: Issues, regulation
and evidence. Economic Policy, 25, 499-544.</mixed-citation>
        </ref>
        <ref id="d434e498a1310">
          
            <mixed-citation id="d434e502" publication-type="other">
Kaiser, U., Mendez, S. J., R0nde, T., &amp; Ullrich, H. (2014). Regulation of pharmaceutical prices: Evidence
from a reference price reform in Denmark. Journal of Health Economics, 36, 174-187.</mixed-citation>
        </ref>
        <ref id="d434e512a1310">
          
            <mixed-citation id="d434e516" publication-type="other">
Lee, Y.-C., Yan, M.-C, Huang, Y.-T., Liu, C.-H., &amp; Chen, S.-B. (2006). Impacts of cost-containment strategies
on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeco-
nomics, 24, 891-902.</mixed-citation>
        </ref>
        <ref id="d434e530a1310">
          
            <mixed-citation id="d434e534" publication-type="other">
Mian, A., &amp; Sufi, A. (2012). The effects of fiscal stimulus: Evidence from the 2009 cash for clunkers program.
Quarterly Journal of Economics, 127, 1107-1142.</mixed-citation>
        </ref>
        <ref id="d434e544a1310">
          
            <mixed-citation id="d434e548" publication-type="other">
Ministry of Health and Social Affairs. (2009a). Regeringens proposition 2008/09: 145, Omieglering av apoteks-
marknaden [The government's bill 2008/09: 145, reregulation of the pharmacy market (in Swedish), http 7/
www.regeringen.se.</mixed-citation>
        </ref>
        <ref id="d434e561a1310">
          
            <mixed-citation id="d434e565" publication-type="other">
Ministry of Health and Social Affairs (2009b). Lag (2009:373) om ändring i lagen (2002:160) om läkemedels-
förmäner m.m. [Law (2009:373) about change in law (2002:160) regarding the pharmaceutical benefit
scheme etc.] (in Swedish), http://www.riksdagen.se.</mixed-citation>
        </ref>
        <ref id="d434e578a1310">
          
            <mixed-citation id="d434e582" publication-type="other">
Ong, M., Catalano, R., &amp; Hartig, T. (2003). A time-series analysis of increased copayments on the prescription
of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clinical Therapeutics, 25,
1262-1275.</mixed-citation>
        </ref>
        <ref id="d434e595a1310">
          
            <mixed-citation id="d434e599" publication-type="other">
Pavcnik, N. (2002). Do pharmaceutical prices respond to potential patient out-of-pocket expenses? RAND
Journal of Economics, 33, 469-487.</mixed-citation>
        </ref>
        <ref id="d434e609a1310">
          
            <mixed-citation id="d434e613" publication-type="other">
Puig-Junoy, J. (2007). The impact of generic reference pricing interventions in the statin market. Health Policy,
84, 14-29.</mixed-citation>
        </ref>
        <ref id="d434e624a1310">
          
            <mixed-citation id="d434e628" publication-type="other">
Puig-Junoy, J. (2010). Impact of European pharmaceutical price regulation on generic price competition: A
review. Pharmacoeconomics, 28, 649-663.</mixed-citation>
        </ref>
        <ref id="d434e638a1310">
          
            <mixed-citation id="d434e642" publication-type="other">
Statskontoret. (2013). En omreglerad apoteksmarknad (in Swedish). Final report, 2013, 7.</mixed-citation>
        </ref>
        <ref id="d434e649a1310">
          
            <mixed-citation id="d434e653" publication-type="other">
Tillväxtanalys. (2014). Apoteksmarknadensomreglering -Effekter pâ följsamhet, priser och kostnader per
dagsdos (in Swedish). Working Paper 2012:19.</mixed-citation>
        </ref>
        <ref id="d434e663a1310">
          
            <mixed-citation id="d434e667" publication-type="other">
Vârdanalys. (2014). Lât den rätte komma in (in Swedish). Report, 2014, 3.</mixed-citation>
        </ref>
        <ref id="d434e674a1310">
          
            <mixed-citation id="d434e678" publication-type="other">
Yfantopoulos, J. (2008). Pharmaceutical pricing and reimbursement reforms in Greece. European Journal of
Health Economics, 9, 87-97.</mixed-citation>
        </ref>
      </ref-list>
    
  </back>
</article>


